Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study

Benzinga Newsdesk www.benzinga.com Positive 61.3%

Neg 0% Neu 0% Pos 61.3%

Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer